.svg)
Tiglylglycine: An internal metabolite, not an ingested toxin
Tiglylglycine (often abbreviated TG) is an acylglycine — a small molecule your body produces when it couples glycine to tiglyl‑CoA, an intermediate in the breakdown of the amino acid isoleucine. In practical terms, it’s a “metabolic breadcrumb” that shows up in urine when certain energy pathways run faster, get backed up, or are stressed. Clinical laboratories typically measure tiglylglycine in urine using mass spectrometry and report it relative to creatinine to account for hydration. Because urine reflects what your body has been processing recently, tiglylglycine is best viewed as a near‑term snapshot of metabolic state rather than a long‑term body burden.
Why it matters: tiglylglycine can rise when mitochondria — the cell’s power plants — are under strain, when isoleucine catabolism is impaired, or in some inborn errors of metabolism. Short‑term spikes may also appear with catabolic states like fasting, fever, or very intense exercise. Certain medications and toxins can influence these pathways indirectly by altering mitochondrial enzymes or liver handling, though human data vary by exposure and more research is needed. In healthy conditions, tiglylglycine tends to be low or near trace levels; persistent elevations can be a clue to look more broadly at energy metabolism, liver–kidney function, and potential contributors in the diet and environment.
Why tiglylglycine is worth measuring
Mitochondria power everything from brain work to workout recovery. When the pathways that burn amino acids and fats run smoothly, intermediates like tiglyl‑CoA move along quietly. When there’s a bottleneck, your body offloads some of that traffic as acylglycines that spill into urine — tiglylglycine among them. Measuring TG helps separate incidental, short‑lived shifts (a tough interval session, a missed meal, a viral bug) from a sustained pattern that could align with symptoms such as fatigue, reduced exercise tolerance, or nonspecific brain fog. It can also complement occupational or environmental assessments, because some stressors are mitochondria‑active and may nudge these pathways, even if they aren’t the sole cause of symptoms.
Big picture: no single molecule tells the whole story. Tiglylglycine finds its best footing alongside related organic acids, acylcarnitines, liver and kidney markers, and your lived context. Patterns — not one‑off values — guide risk over time. Tracking TG with other data helps distinguish transient spikes from persistent metabolic stress and supports smarter decisions with your clinician about whether additional testing or environmental changes are warranted.
Who benefits most from tiglylglycine testing
Consider tiglylglycine when you’re exploring unexplained fatigue or recovery issues, evaluating possible mitochondrial stress, or mapping patterns alongside broader organic acids. It can add context during high‑exposure occupations in which mitochondrial stressors are plausible, during pregnancy when metabolic demands shift, or when monitoring known inborn errors of metabolism under clinical supervision. In the era of intense interest in metabolic health — from protein targets to GLP‑1 medications — TG offers a grounded, mechanistic window into how your energy pathways are actually handling their workload.
Reading a tiglylglycine result
Laboratories usually report tiglylglycine as a urine value indexed to creatinine and compared with a population‑based reference interval. For metabolites linked to energy stress, lower values are generally preferable when feasible. Because TG reflects recent physiology, interpretation improves with timing notes (meals, workouts, illness) and, when needed, repeat testing.
When tiglylglycine is relatively lower or within the lab’s typical range, it suggests limited recent buildup of isoleucine‑related intermediates and a lower likelihood of short‑term mitochondrial strain. Many healthy people have TG at low or near‑trace levels. In pregnancy and early childhood, renal handling and growth demands shift metabolism; values can differ modestly and merit clinician context rather than strict one‑size‑fits‑all cutoffs.
When tiglylglycine is relatively higher, it can indicate recent or ongoing metabolic stress — for example, catabolic states from fasting or illness, very intense training, or impaired processing along the isoleucine pathway. The liver and kidneys help clear these metabolites, so elevations may travel with other signs of detoxification and clearance workload. Depending on the whole pattern, symptoms may surface in energy systems (fatigue, exercise intolerance), neurologic performance (concentration dips), or recovery capacity. A single result shouldn’t carry all the weight; trends over weeks to months, plus related biomarkers, provide the signal from the noise.
What can shift a tiglylglycine reading
This is a urine test analyzed by mass spectrometry and typically normalized to creatinine to adjust for hydration. First‑morning or timed collections reduce variability from recent meals and activity. Results generally reflect the prior 24–48 hours. If you’re tracking a change — like a new training block, a period of fasting, or a workplace exposure assessment — repeating the test under similar conditions helps clarify directionality.
Tiglylglycine is an internal metabolite, not a toxin you ingest. Still, it can rise in settings where mitochondria work harder or less efficiently. Some environmental and pharmaceutical exposures are known to affect mitochondrial enzymes, but their impact on TG specifically varies and evidence in everyday exposures is evolving. Use TG as one piece of a larger, evidence‑based puzzle. If your level is persistently elevated or climbs together with related markers, that’s a strong cue to review recent stressors, product and workplace exposures, diet and training loads, and to decide — with your clinician — whether additional testing is appropriate.
What a tiglylglycine test can and can't tell you
The take‑home: tiglylglycine is most meaningful when combined with other environmental and metabolic markers, general health indicators, and what’s happening in your life. Over time, that integrated view helps separate transient blips from persistent patterns and supports safer, more effective next steps with your clinician.
FAQs
This test measures the concentration of tiglylglycine, an acylglycine metabolite, in biological fluids to detect metabolic abnormalities.
Elevated tiglylglycine reflects impaired isoleucine (branched‑chain amino acid) catabolism and is seen in certain organic acidemias, serving as a marker of disrupted mitochondrial/organic acid metabolism.
Yes — test for tiglylglycine (TG) when there are clues of abnormal energy metabolism or unexplained symptoms: TG is an acylglycine produced when isoleucine catabolism or mitochondrial fatty‑acid oxidation is disrupted, so elevated TG can flag inherited metabolic disorders or acquired mitochondrial dysfunction. This matters for health and longevity because mitochondria drive cellular energy, repair, and detoxification; persistent mitochondrial dysfunction is linked to fatigue, developmental problems, organ stress and may accelerate age‑related decline, so detecting TG can reveal a metabolic bottleneck that influences long‑term resilience.
Sources and impacts: TG elevations most often reflect internal metabolic blocks (genetic enzyme defects) but can also appear secondarily when mitochondrial enzymes are inhibited by environmental or pharmaceutical exposures — for example certain pesticides, solvents, heavy metals, or some medications — or by severe nutritional stress. Possible health impacts include episodic metabolic decompensation in susceptible people, chronic low energy, muscle weakness, and contributions to broader metabolic or developmental issues. Testing helps distinguish a primary metabolic/genetic cause from an acquired exposure effect, enabling targeted follow‑up (dietary, medical, or exposure‑reduction strategies) and ongoing monitoring rather than guesswork.
Who benefits most: newborns or people with unexplained developmental delays or metabolic symptoms, individuals with known or suspected mitochondrial or fatty‑acid oxidation disorders, people with high environmental or occupational exposure risk (e.g., certain pesticides, solvents, heavy metals), those with unexplained chronic fatigue or multisystem complaints, and people focused on fertility, thyroid function, detox capacity, or longevity optimization who want to clarify metabolic/mitochondrial status. Testing is practical for diagnosis and prioritizing exposure‑reduction or specialist referral but is informational rather than prescriptive on its own.
Test once to establish a baseline exposure to tiglylglycine (TG), then perform periodic follow-up testing if levels are elevated (commonly every 3–6 months until levels decline) and any time you make significant lifestyle or environment changes—for example, after changing household products or following detoxification efforts—or after a known exposure.
Results can be affected by timing of sample collection, recent exposures (food, air, water, or consumer products), individual metabolism, hydration status, and the sample type collected (urine versus blood); certain medications or supplements may also influence readings.
Fasting is typically not required for tiglylglycine (TG) testing; if the lab is measuring TG in urine, a first‑morning urine sample is often preferred because it is more concentrated and gives more consistent results—however, follow any specific instructions from the ordering clinician or laboratory.
Avoid contaminating the specimen: do not apply creams, lotions or other personal‑care products to the collection area immediately before a urine sample, rinse hands well, and use a clean catch technique. It’s also helpful to note and report recent product use or environmental contact (for example contact with plastics, personal care items, pesticides, solvents or unusual workplace exposures), plus recent topical medications or household chemical use, so the lab can interpret possible contamination or exposure-related interference.
Tiglylglycine (TG) testing is generally reliable as a marker of recent metabolic processing of the parent compound, but it more strongly reflects recent exposure or short‑term metabolic changes rather than long‑term body burden. Results can indicate that exposure has occurred and show relative changes over time, but a single TG measurement is limited for assessing cumulative lifetime burden.
Accuracy depends critically on sample timing (how soon after exposure the sample is taken), the laboratory method used (high‑quality methods such as mass spectrometry improve specificity and sensitivity), and consistency of collection, handling and storage (time of day, sample type, preservatives, and chain of custody). For best interpretation, use standardized collection procedures, a lab that uses validated MS‑based assays, and, when needed, repeat or complementary testing and clinical correlation.
References
- Bennett, M. J., Powell, S., Swartling, D. J., & Gibson, K. M. (1994). Tiglylglycine excreted in urine in disorders of isoleucine metabolism and the respiratory chain measured by stable isotope dilution GC-MS. Clinical Chemistry, 40(10), 1879-1883. https://pubmed.ncbi.nlm.nih.gov/7923765/
- la Marca, G., & Rizzo, C. (2011). Analysis of organic acids and acylglycines for the diagnosis of related inborn errors of metabolism by GC- and HPLC-MS. Methods in Molecular Biology, 708, 73-98. https://doi.org/10.1007/978-1-61737-985-7_4
- Wojcik, M. H., Wierenga, K. J., Rodan, L. H., Sahai, I., Ferdinandusse, S., Genetti, C. A., Towne, M. C., Peake, R. W. A., James, P. M., Beggs, A. H., Brownstein, C. A., Berry, G. T., & Agrawal, P. B. (2017). Beta-ketothiolase deficiency presenting with metabolic stroke after a normal newborn screen in two individuals. JIMD Reports, 39, 45-54. https://doi.org/10.1007/8904_2017_45
- Barr, D. B., Wilder, L. C., Caudill, S. P., Gonzalez, A. J., Needham, L. L., & Pirkle, J. L. (2005). Urinary creatinine concentrations in the U.S. population: Implications for urinary biologic monitoring measurements. Environmental Health Perspectives, 113(2), 192-200. https://doi.org/10.1289/ehp.7337
- O'Brien, K. M., Upson, K., Cook, N. R., & Weinberg, C. R. (2016). Environmental chemicals in urine and blood: Improving methods for creatinine and lipid adjustment. Environmental Health Perspectives, 124(2), 220-227. https://doi.org/10.1289/ehp.1509693
.avif)
.svg)
.svg)
